

# Martin Eklund

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/15625/martin-eklund-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85  
papers

2,193  
citations

22  
h-index

46  
g-index

103  
ext. papers

3,460  
ext. citations

9  
avg, IF

5.02  
L-index

#	Paper	IF	Citations
85	Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge.. <i>Nature Medicine</i> , <b>2022</b> ,	50.5	14
84	Clinical trial design during and beyond the pandemic: the I-SPY COVID trial.. <i>Nature Medicine</i> , <b>2022</b> ,	50.5	0
83	Mortality in men with castration-resistant prostate cancer-A long-term follow-up of a population-based real-world cohort.. <i>BJUI Compass</i> , <b>2022</b> , 3, 173-183	0.9	1
82	A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study.. <i>European Urology Open Science</i> , <b>2022</b> , 38, 32-39	0.9	1
81	Detection of perineural invasion in prostate needle biopsies with deep neural networks.. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2022</b> , 1	5.1	0
80	Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists.. <i>Scandinavian Journal of Urology</i> , <b>2022</b> , 1-7	1.6	
79	Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer. <i>World Journal of Urology</i> , <b>2021</b> , 39, 1797-1804	4	5
78	Artificial Intelligence in Magnetic Resonance Imaging-based Prostate Cancer Diagnosis: Where Do We Stand in 2021?. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	3
77	Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators. <i>European Urology Focus</i> , <b>2021</b> , 7, 546-553	5.1	5
76	Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1899-1908	2.2	10
75	Real world treatment utilization patterns in patients with castration-resistant prostate cancer. <i>Scandinavian Journal of Urology</i> , <b>2021</b> , 55, 299-306	1.6	1
74	Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer in Biopsies-Current Status and Next Steps. <i>European Urology Focus</i> , <b>2021</b> , 7, 687-691	5.1	2
73	Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists. <i>Modern Pathology</i> , <b>2021</b> , 34, 660-671	9.8	22
72	Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 120-127	6.2	3
71	Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2021</b> , 24, 457-464	6.2	
70	Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS). <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 632-640	9.7	6
69	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , <b>2021</b> , 53, 65-75	36.3	62

68	The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects. <i>European Urology Open Science</i> , <b>2021</b> , 24, 43-51	0.9	
67	Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms. <i>European Urology Open Science</i> , <b>2021</b> , 24, 11-16	0.9	1
66	Interobserver reproducibility of perineural invasion of prostatic adenocarcinoma in needle biopsies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2021</b> , 478, 1109-1116	5.1	2
65	MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 908-920	59.2	42
64	Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1240-1249	21.7	11
63	Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 477, 777-786	5.1	10
62	The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. <i>Trials</i> , <b>2020</b> , 21, 579	2.8	5
61	Association between PSA density and prostate cancer in men without significant MRI lesions. <i>BJU International</i> , <b>2020</b> , 125, 763-764	5.6	3
60	Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA $\leq$ ng/ml. <i>Scandinavian Journal of Urology</i> , <b>2020</b> , 54, 1-6	1.6	2
59	The economic burden of prostate cancer - a Swedish prevalence-based register study. <i>BMC Health Services Research</i> , <b>2020</b> , 20, 448	2.9	9
58	Factors Contributing to Healthcare Professional Burnout During the COVID-19 Pandemic: A Rapid Turnaround Global Survey <b>2020</b> ,		20
57	Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 222-232	21.7	154
56	Comparison of a Deep Learning Risk Score and Standard Mammographic Density Score for Breast Cancer Risk Prediction. <i>Radiology</i> , <b>2020</b> , 294, 265-272	20.5	42
55	Response to Carter et al. <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkaa016	4.6	
54	Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy. <i>Journal of Clinical Pathology</i> , <b>2020</b> , 73, 630-635	3.9	4
53	Range of Radiologist Performance in a Population-based Screening Cohort of 1 Million Digital Mammography Examinations. <i>Radiology</i> , <b>2020</b> , 297, 33-39	20.5	7
52	Factors contributing to healthcare professional burnout during the COVID-19 pandemic: A rapid turnaround global survey. <i>PLoS ONE</i> , <b>2020</b> , 15, e0238217	3.7	164
51	External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1581-1588	13.4	55

50	Effect of artificial intelligence-based triaging of breast cancer screening mammograms on cancer detection and radiologist workload: a retrospective simulation study. <i>The Lancet Digital Health</i> , <b>2020</b> , 2, e468-e474	14.4	40
49	Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer. <i>European Urology Oncology</i> , <b>2020</b> , 3, 640-647	6.7	8
48	Factors contributing to healthcare professional burnout during the COVID-19 pandemic: A rapid turnaround global survey <b>2020</b> , 15, e0238217		
47	Factors contributing to healthcare professional burnout during the COVID-19 pandemic: A rapid turnaround global survey <b>2020</b> , 15, e0238217		
46	Factors contributing to healthcare professional burnout during the COVID-19 pandemic: A rapid turnaround global survey <b>2020</b> , 15, e0238217		
45	Factors contributing to healthcare professional burnout during the COVID-19 pandemic: A rapid turnaround global survey <b>2020</b> , 15, e0238217		
44	Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI. <i>BMJ Open</i> , <b>2019</b> , 9, e027816	3	10
43	Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0218280	3.7	2
42	A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging. <i>European Urology Oncology</i> , <b>2019</b> , 2, 490-496	6.7	8
41	The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study. <i>BMJ Open</i> , <b>2019</b> , 9, e027958	3	6
40	A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data. <i>PLoS ONE</i> , <b>2019</b> , 14, e0211918	3.7	5
39	Prognostic factors for digital range of motion after intrasynovial flexor tendon injury and repair: Long-term follow-up on 273 patients treated with active extension-passive flexion with rubber bands. <i>Journal of Hand Therapy</i> , <b>2019</b> , 32, 328-333	1.6	5
38	Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?. <i>BMC Urology</i> , <b>2019</b> , 19, 73	2.2	
37	The importance of study design in the application of artificial intelligence methods in medicine. <i>Npj Digital Medicine</i> , <b>2019</b> , 2, 101	15.7	2
36	Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1914689	10.4	11
35	The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2019</b> , 22, 137-142	6.2	14
34	Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 1195-1204	7.5	18
33	Reply to Erik Rud, Peter Lauritzen, and Eduard Baco Letter to the Editor re: Henrik Gröbberg, Martin Eklund, Wolfgang Picker, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. <i>Eur Urol</i> 2018;74:722-8. <i>European Urology</i> , <b>2019</b> , 75, e104-e105	10.2	

32	Response to Walsh. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 748	9.7	
31	The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. <i>European Urology</i> , <b>2018</b> , 74, 204-210	10.2	47
30	Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2018</b> , 21, 57-63	6.2	73
29	Reply to Ola Bratt and Anna Everholm Letter to the Editor re: Peter Ström, Tobias Nordström, Henrik Gråberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2017.12.028">https://doi.org/10.1016/j.eururo.2017.12.028</a> ; <i>European Urology</i> , <b>2018</b> , 74, e10-e11	10.2	
28	Affinity proteomic profiling of plasma for proteins associated to area-based mammographic breast density. <i>Breast Cancer Research</i> , <b>2018</b> , 20, 14	8.3	5
27	Risk of Prostate Cancer in Men Treated With 5 $\alpha$ Reductase Inhibitors-A Large Population-Based Prospective Study. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 1216-1221	9.7	18
26	Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model. <i>European Urology Focus</i> , <b>2018</b> , 4, 385-387	5.1	7
25	The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing. <i>European Urology Focus</i> , <b>2018</b> , 4, 707-710	5.1	30
24	Summary statement on screening for prostate cancer in Europe. <i>International Journal of Cancer</i> , <b>2018</b> , 142, 741-746	7.5	19
23	Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. <i>European Urology</i> , <b>2018</b> , 74, 722-728	10.2	49
22	Predictors of participation in risk-based prostate cancer screening. <i>PLoS ONE</i> , <b>2018</b> , 13, e0200409	3.7	6
21	Re: Tobias Nordström, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Gråberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>Eur Urol</i> 2015;68:139-46. <i>European Urology</i> , <b>2018</b> , 74, e35-e36	10.2	2
20	Effects of pre-notification, invitation length, questionnaire length and reminder on participation rate: a quasi-randomised controlled trial. <i>BMC Medical Research Methodology</i> , <b>2018</b> , 18, 3	4.7	18
19	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , <b>2018</b> , 50, 928-936	36.3	340
18	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , <b>2018</b> , 9, 2256	17.4	57
17	The WISDOM Personalized Breast Cancer Screening Trial: Simulation Study to Assess Potential Bias and Analytic Approaches. <i>JNCI Cancer Spectrum</i> , <b>2018</b> , 2, pky067	4.6	13
16	E-Science technologies in a workflow for personalized medicine using cancer screening as a case study. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2017</b> , 24, 950-957	8.6	3
15	Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	102

14	Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy. <i>BMC Urology</i> , <b>2017</b> , 17, 92	2.2	2
13	Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project. <i>European Urology Focus</i> , <b>2017</b> , 3, 526-528	5.1	10
12	Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study-Gråberg H et al. <i>Lancet Oncology</i> . 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7. <i>World Journal of Urology</i> , <b>2017</b> , 35, 895-896	4	
11	Public interest in and acceptability of the prospect of risk-stratified screening for breast and prostate cancer. <i>Acta Oncologica</i> , <b>2016</b> , 55, 45-51	3.2	24
10	Association of changing prostate-specific antigen (PSA) levels on repeat testing with lower risk for Gleason Score (GS) $\geq$ 7 prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 284-284	2.2	
9	The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments. <i>Nature Reviews Clinical Oncology</i> , <b>2016</b> , 13,	19.4	5
8	Population-based screening for cancer: hope and hype. <i>Nature Reviews Clinical Oncology</i> , <b>2016</b> , 13, 550-659	6.4	64
7	Repeat Prostate-Specific Antigen Tests Before Prostate Biopsy Decisions. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	9
6	Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>European Urology</i> , <b>2015</b> , 68, 139-46	10.2	123
5	Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 1667-76	21.7	228
4	Prediction of individual genetic risk to prostate cancer using a polygenic score. <i>Prostate</i> , <b>2015</b> , 75, 1467-74	7.4	43
3	Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines. <i>Annals of Internal Medicine</i> , <b>2014</b> , 160, 145	8	60
2	A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml. <i>European Urology</i> , <b>2014</b> , 65, 1184-90	10.2	24
1	Transcriptome-wide prediction of prostate cancer gene expression from histopathology images using co-expression-based convolutional neural networks. <i>Bioinformatics</i> ,	7.2	1